Denmark to permanently legalize medical cannabis

29 November 2024

The Danish Ministry of Interior and Health has announced that the political parties have decided to permanently legalize treatment with medical cannabis in Denmark. When the Danish Pilot Program expires in December 2025, the Danish Parliament will enact legislation to ensure the permanent legalization of medical cannabis treatment for patients.

This is fantastic news for Danish patients, who now have certainty that they can continue their treatment, said medical cannabis maker Stenocare, adding that it also provides a positive outlook for the Danish domestic market, where the company has been a leading supplier of prescription medical cannabis since 2018.

Minister of Interior and Health, Sophie Løhde, commented on the agreement noting: "Medical cannabis has proven to be a sought-after alternative to authorized medication for patients with serious diseases such as cancer and multiple sclerosis. Many experiences relief from pain or nausea that can significantly improve their quality of life. And with this agreement, we ensure that patients who have not had sufficient effect from other treatments will continue to be able to be prescribed medical cannabis by a doctor in a safe environment.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical